Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2020.1767585
Abstract: ABSTRACT Introduction The management of patients affected by autoimmune/idiopathic diseases has been revolutionized by the development of targeted therapies (TT). However, the use of TT is complicated by several adverse events, like opportunistic infections (OIs).… read more here.
Keywords: autoimmune idiopathic; management opportunistic; therapies autoimmune; management ... See more keywords
Immune therapies for autoimmune diabetes targeting pathogenic peptide–MHC complexes
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Molecular Cell Biology"
DOI: 10.1093/jmcb/mjaa037
Abstract: At present, there is no cure for type 1A diabetes (T1D), a T cell-mediated autoimmune disease. Monoclonal antibodies (mAbs) are used to treat a wide number of diseases. For treating T1D, mAbs that target major… read more here.
Keywords: mhc complexes; peptide mhc; therapies autoimmune; disease ... See more keywords
Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept
Sign Up to like & getrecommendations! Published in 2022 at "Immune Network"
DOI: 10.4110/in.2022.22.e37
Abstract: Autoimmune diseases are caused by a dysfunction of the acquired immune system. In a subset of autoimmune diseases, B cells escaping immune tolerance present autoantigen and produce cytokines and/or autoantibodies, resulting in systemic or organ-specific… read more here.
Keywords: cell; autoimmune diseases; engineering cell; therapies autoimmune ... See more keywords